SCHEMBL22022917

SCHEMBL22022917

O=C(Cc1ccc(-c2cccnc2)cc1)Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 2/20 0.63
▸ KDM5A P29375 1/20 0.63
▸ KDM5B Q9UGL1 1/20 0.63
▸ ACLY P53396 1/20 0.60
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ GRIK1 P39086 4/20 0.57
▸ KDM6B O15054 1/20 0.54
▸ KDM4D Q6B0I6 1/20 0.54
▸ WNT3A P56704 2/20 0.54
▸ PORCN Q9H237 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ MAP4K4 O95819 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ NTRK1 P04629 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ FYN P06241 1/20 0.49
▸ CSF1R P07333 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22022888 0.90 GRIK1 (0.56) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022931 0.89 HCAR2 (0.62) KDM4CACLYGRIK1KDM6BKDM4D
SCHEMBL22022864 0.89 ACLY (0.75) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022897 0.84 MEN1 (0.58) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022924 0.83 MEN1 (0.60) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022933 0.83 MEN1 (0.68) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022868 0.83 KMT2A (0.68) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022874 0.82 HCAR2 (0.56) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL1309256 0.82 MEN1 (0.78) KDM4CKDM5AKDM5BACLYMEN1
SCHEMBL22022916 0.82 MEN1 (0.70) KDM4CKDM5AKDM5BACLYMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
EP-3890734-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-10-13 — — EP disclosed
WO-2020115019-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2020-06-11 — — WO disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES KCNK2, KCNT2, KCNT1 KDM4C 2740/4885KDM5A 1698/4885KDM5B 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback